Bioline Rx Ltd BLRX

NAS: BLRX | ISIN: US09071M2052   10/05/2024
0,652 USD (-4,83%)
(-4,83%)   10/05/2024

6 mei 2024 · BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 · Persbericht

17 april 2024 · BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting · Persbericht

10 april 2024 · BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement · Persbericht

1 april 2024 · BioLineRx Announces $6 Million Registered Direct Offering · Persbericht

26 maart 2024 · BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

20 maart 2024 · BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 · Persbericht

4 maart 2024 · BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production · Persbericht

28 februari 2024 · BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) · Persbericht

16 februari 2024 · BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® · Persbericht

21 december 2023 · BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease · Persbericht

13 november 2023 · BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 · Persbericht

1 november 2023 · BioLineRx a conclu un accord de licence exclusive concernant le motixafortide en Asie, sur les conseils de MSQ Ventures · Persbericht

31 oktober 2023 · BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures · Persbericht

12 oktober 2023 · BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment · Persbericht

3 oktober 2023 · Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals? · Persbericht

2 oktober 2023 · Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals? · Persbericht

29 september 2023 · Thinking about buying stock in Femasys, Community Health Systems, Opendoor Technologies, Capstone Green Energy, or BioLine RX Ltd? · Persbericht

28 september 2023 · BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) · Persbericht

25 september 2023 · Thinking about buying stock in Mullen Automotive, BioLine RX, Research Solutions, Euroseas, or Virco Mfg? · Persbericht

19 september 2023 · BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer · Persbericht

Mijn selecties